At a glance
ClinicalIndex Comparison RecordPhase 2Active· 70 enrolled
Drug / intervention
Taselisibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
MATCH Treatment Subprotocol I: GDC-0032 (Taselisib) in Patients With Tumors (Other Than Breast Cancer) With PIK3CA Mutation But Without KRAS Mutation or PTEN Loss
In Brief
A Phase 2 clinical trial evaluating Taselisib for Advanced Lymphoma and 5 related conditions. Active but no longer recruiting, targeting 70 participants across 1 site.
Detailed Summary
This phase II MATCH treatment trial identifies the effects of GDC-0032 (taselisib) in patients whose cancer has a genetic change called PIK3CA mutation. Taselisib may stop the growth of cancer cells by blocking PIK3CA, a protein that may be needed for cell growth. Researchers hope to learn if taselisib will shrink this type of cancer or stop its growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
CountriesUnited States
Collaborators--
Timeline
Phase 2Active
201620172018201920202021202220232024202520262027
Enrollment StartFeb 2016
First PostedJun 2020
Primary CompletionNov 2020
TodayJul 2026
Study CompletionMar 2027
First PostedJun 19, 2020
Enrollment StartFeb 25, 2016
Primary CompletionNov 10, 2020
Study CompletionMar 31, 2027
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 6.0 years ago
Interventions
Taselisibdrug
Given PO